Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Supplementation to Enhance Recovery in Bladder Cancer
NCT03204266Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Participant Compliance at 21 days. Started Aug 2017; status: completed.
Beyond the preview
Go deeper on NCT03204266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204266.